APR 13, 2016 2:41 PM PDT

Turning Lymphocytes Into Rapidly Dividing Attack Cells

WRITTEN BY: Kara Marker
A new hope for vaccine development and cancer therapy has been identified, and it is a signaling protein called c-Myc that plays a regulatory role in the production of daughter cells in the immune system.
 
Asymmetric cell division produces two cell types rather than two identical daughter cells. When this happens, both effector T cells and memory T cells can be produced during cell division. Both of these lymphocytes are important in the fight against invading pathogens.
 
Effector T cells are like armed warriors recruited by the immune system to attack and kill bacteria and viruses. These lymphocytes divide quickly and differentiate further into subtypes specifically designed to kill certain pathogens. Memory T cells are essentially a whole new species, dividing slowly and serving to maintain long-term protection from ongoing infections.
 
T cells fate is influenced by the expression c-Myc protein (green)

In a new study from the St. Jude Children’s Research Hospital, published in Nature, scientists discovered for the first time the link between asymmetric cell division and c-Myc signaling protein. After looking at both cells in culture and in mice, they saw accumulation of c-Myc in the asymmetrically dividing cells, prompting the rapid proliferation of effector T cells like a “shot of caffeine.”
 
"Activated T cells divide every four to six hours. There is no other cell in adults that can divide that fast, not even cancer cells,” said corresponding author Douglas Green, PhD, St. Jude Department of Immunology chair.
 
Mice with decreased levels of c-Myc, on the other hand, had a larger population of memory T cells, an immunological army helpful for the onset of a much later infection but not for an immediate attack.
 
Playing a pivotal role in cell growth, differentiation, and apoptotic death in tissues all over the body, c-Myc is a crucial regulator of cell division. The scientists from this study saw mutations in c-Myc leading to metabolic changes after T cells were activated, which soon led them to believe that learning to control c-Myc could be beneficial to human health The regulation surrounding asymmetric cell division seems to be in the form of a positive feedback loop, and the St. Jude’s scientists believe that manipulation of the metabolic and signaling pathways that lead to c-Myc production could help with vaccine and immunotherapy production for treating cancer.
 
"While daughter cells of activated T cells seem to have very different fates, we showed their behavior could be altered by manipulating these metabolic and regulatory pathways to increase or decrease c-Myc levels." Green said.
 
 
Source: St. Jude Children’s Research Hospital, ImmunoBiology
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
MAR 23, 2020
Drug Discovery & Development
MAR 23, 2020
Top 5 Candidates for Coronavirus Vaccine Around the World
It’s easy to complain about the role of big pharma in medicine-making and the hassle of dealing with protective pa ...
MAR 16, 2020
Drug Discovery & Development
MAR 16, 2020
Critical Interleukin Leads to Drug Discovery
The immune molecule interleukin-2 (IL-2) is a growth factor that stimulates the immune system to produce T-cells. Their ...
MAR 28, 2020
Drug Discovery & Development
MAR 28, 2020
FDA Approves 5-Minute Coronavirus Test
In recent weeks, the US has struggled to supply enough tests to detect the coronavirus. Now, however, this may change th ...
APR 07, 2020
Microbiology
APR 07, 2020
Second COVID-19 Vaccine Enters Human Trials
Yesterday, Inovio Pharmaceuticals, Inc. announced that it will begin human trials on a potential vaccine for COVID-19.
APR 13, 2020
Cannabis Sciences
APR 13, 2020
Smoking Cannabis Increases COVID-19 Risk
Health experts from the National Institute on Drug Abuse and the American Lung Association have said that smoking cannab ...
APR 11, 2020
Drug Discovery & Development
APR 11, 2020
Promising Experimental Anti-Malarial Drug
At St. Jude Children’s Research Hospital, researchers discovered a fast-acting anti-malarial compound with promisi ...
Loading Comments...